Although U0126 was reported to be protective against sorafenib-induced cytotoxicity in hepatocellular carcinoma (HCC) cells, combination of sorafenib with another MEK inhibitor CI-1040 was synergistic associated with increased Bim in HCC cells [39, 40]. This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.